Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BCA101||BCA-101|BCA 101||EGFR Antibody 53 TGFB (Pan) Antibody 5||BCA101 is a bifunctional antibody that targets both EGFR and TGFB and leads to inhibition of downstream signaling, which may lead to inhibition of tumor cell proliferation and activation of anti-tumor immune response (PMID: 37074042).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF act mut||colorectal cancer||sensitive||BCA101||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with BCA101 resulted in a tumor growth inhibition of 31% compared to 8% with Erbitux (cetuximab) in a BRAF-mutant colorectal cancer cell line and human peripheral blood mononuclear cells coimplantation xenograft model (PMID: 37074042).||37074042|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04429542||Phase I||BCA101 BCA101 + Pembrolizumab||Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors||Recruiting||USA | CAN||0|